Arkolith/Insider Trading/QNCX/Form 4

Thye Dirk

CHIEF EXECUTIVE OFFICER, DirectorQuince Therapeutics, Inc. (QNCX) · full profile →Form 4 · filed Jan 17, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 16, 2024Option exercise(M)150K$0.94$141K689K
Jan 16, 2024Option exercise(M)91K$0.55$50K539K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 16, 2024Option exercise(M)91K—$0116K
Jan 16, 2024Option exercise(M)150K—$0450K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-001313) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML